Savara Pharmaceuticals

Savara is a clinical stage pharmaceutical company focused on developing and commercializing therapies for patients with respiratory diseases that are inadequately treated with currently available medicines.

The company’s lead therapy is dry powder inhalable form of an antibiotic for the treatment of MRSA in CF patients and other lung compromised patients. This therapy has successfully completed dosing of volunteers in a  Phase 1 trial and is currently enrolling in a lung pharmacokinetics study in cystic fibrosis patients.

In addition, Savara is applying its proprietary formulation technologies to enable and improve the pulmonary delivery of proven drugs for internal pipeline development and commercial partners.

 

 

 
     
 
News
 

11/4/11

Savara Inc. Joins SAFE-BioPharma Association

8/15/11

Savara Receives Grant Award from National Institute of Allergy and Infectious Diseases

11/8/10

Savara Appoints Richard Hawkins to Board of Directors 


More News >

 

 

 

 

Savara Inc. © 2012 | Privacy Policy | Terms Of Use